Akanda vs 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals is the larger business, with $1.0m of revenue in fiscal 2025 against $258,075 for Akanda (3.9 times as much). 60 Degrees Pharmaceuticals grew faster (65.5% against -69.2%). Akanda kept more of each dollar of sales as profit: a net margin of -467.1% against -732.5%.
| Latest fiscal year | AkandaAKAN, 2025 | 60 Degrees PharmaceuticalsSXTP, 2025 |
|---|---|---|
| Revenue | $258,075 | $1.0m |
| Revenue growth | -69.2% | 65.5% |
| Net income | −$1.2m | −$7.4m |
| Operating margin | -1931.0% | — |
| Net margin | -467.1% | -732.5% |
| Return on equity | — | -196.4% |
| Free cash flow | −$8.0m | −$7.0m |
| Cash | $504,136 | $1.5m |
| Total debt | $1.0m | $152,775 |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $76,159 | $2.6m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 1 buys, 1 sales | 4 buys, 0 sales |